Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 6851814

Corpus cavernosography.

S Frouws·J W Reeders·A A Valcke
View original source ↗Export metadata ↓

Abstract

The cavernous spaces of the penis can be demonstrated by injecting 20 cm3 contrast agent (Urografin 60%) dorsolaterally behind the gland penis. By injecting the contrast agent into one corpus cavernosum, both corpora become visible by X-ray. Pathologic conditions (trauma, Peyronie's disease, priapism, malignancy, etc.) cause typical changes in the cavernous spaces and blood drainage. The literature has been reviewed.

Explore related subjects

Diatrizoate MeglumineHumansMalePenile IndurationPenile NeoplasmsPenisPriapismProstheses and ImplantsRadiographyRuptureJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Frouws, J W Reeders, A A Valcke. 1983. Corpus cavernosography.. https://pubmed.ncbi.nlm.nih.gov/6851814/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

Hepatic cavernous hemangiomas: simple diagnostic sign with dynamic bolus CT.

Many hepatic hemangiomas are discovered incidentally during incremental dynamic bolus computed tomography (CT). To meet the established criteria for diagnosis with CT, however, a second CT examination with single-level dynamic bolus imaging is necessary. A prospective evaluation was performed to examine a simple sign that may be used to diagnose cavernous hemangiomas during incremental dynamic bolus CT. This sign is the visualization of foci of globular enhancement within the hemangioma, analogous to areas of puddling of contrast material seen at angiography. A total of 34 lesions in 21 patients demonstrated foci of globular enhancement. Of the 34 lesions, 32 (94%) proved to be hemangiomas. All 21 patients underwent confirmatory evaluation. Foci of globular enhancement seen during dynamic bolus CT are a strong indication that the lesion is a cavernous hemangioma. This diagnostic sign may obviate further, more expensive imaging studies.

Diatrizoate Meglumine↗
PubMed1992

Comparison of iohexol 300 and diatrizoate meglumine 60 for body CT: image quality, adverse reactions, and aborted/repeated examinations.

Six hundred patients were prospectively randomized and given either diatrizoate meglumine 60 or iohexol 300 during dynamic contrast-enhanced body CT in order to compare image quality, contrast reactions, and the number of aborted studies or studies in which images had to be repeated. Three hundred two patients received iohexol 300, and 298 patients received diatrizoate meglumine 60. Thirty-nine percent (119/302) of the patients given iohexol 300 and 63% (188/298) of the patients given diatrizoate meglumine 60 had at least one adverse reaction thought to be related to contrast material during, or within 24 hr of, the body CT scan. When reactions of discomfort (heat or warmth, flushing, bad taste) were excluded, 16% (48/302) of the patients who received iohexol and 33% (99/298) of the patients who were given diatrizoate meglumine 60 had at least one adverse reaction. The differences in both types of reactions between the two agents were significant (p less than .001). Among scans evaluated for study quality, 71% (214/302) of the iohexol 300 group and 62% (184/298) of the diatrizoate meglumine 60 group had optimal enhancement (p = .02). However, when the optimal and adequate categories were combined, 301 of 302 patients given iohexol 300 and 292 of 298 patients given diatrizoate meglumine 60 had diagnostic-quality studies (no statistical difference). Studies were not terminated nor were images repeated in 97% (292/302) of the patients given iohexol 300 and in 94% (280/298) of those given diatrizoate meglumine 60. The CT study was repeated because of movement during the contrast injection or aborted because of contrast-related reactions in 0.7% of the patients given iohexol 300 and in 3.0% of the patients given diatrizoate meglumine 60. This difference was statistically significant (p = .04). Our results suggest that the difference in image quality, number of adverse reactions, and number of aborted/repeated CT scans performed with iohexol 300 or diatrizoate meglumine 60 are not sufficiently different to warrant conversion to nonionic agents for body CT scans.

Diatrizoate Meglumine↗